EICHOR
● Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Condition: Ovarian Cancer · Sponsor: AbbVie
About this study
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in participants with ovarian cancer (OC). Participants must have confirmation of folate receptor alpha (FRa) positivity by the Ventana folate receptor 1 (FOLR1) Assay. Mirvetuximab Soravtansine (MIRV) is an investigational drug for the treatment of OC. Participants will be assigned to 1 of 3 substudies and further into groups called treatment arms. In substudy 1, arms A-C, participants will receive 1 of 2 doses of MIRV with Bev, or Bev alone. In substudy 2, arms D and E, participants will receive 1 of 2 doses of MIRV with carboplatin, followed by MIRV alone. In substudy 3, arms F and G, participants will receive one of two doses of MIRV with BEV and carboplatin, followed by MIRV with BEV. Approximately 400 participants will be enrolled in the study at 100 sites around the world. Participants will receive intravenously (IV) infused MIRV with IV infused carboplatin, or IV infused Bev, or IV infused carboplatin and Bev, or IV infused Bev alone. The total study duration will be approximately 40 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and ma…
This description comes directly from the study's public registry record.
Talk to the study team
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
Locations (80)
| UC San Diego Health - Moores Cancer Center /ID# 277574 | La Jolla, California, United States | Recruiting |
| Sansum Clinic - Solvang /ID# 277712 | Solvang, California, United States | Active Not Recruiting |
| University of Florida College of Medicine /ID# 278348 | Gainesville, Florida, United States | Recruiting |
| Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623 | Orlando, Florida, United States | Recruiting |
| Florida Cancer Specialists - North /ID# 278626 | St. Petersburg, Florida, United States | Recruiting |
| Florida Cancer Specialists - East /ID# 278605 | West Palm Beach, Florida, United States | Recruiting |
| Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440 | Baton Rouge, Louisiana, United States | Recruiting |
| Maine Medical Center - Scarborough Campus /ID# 277205 | Scarborough, Maine, United States | Recruiting |
| Karmanos Cancer Institute - Detroit /ID# 277085 | Detroit, Michigan, United States | Recruiting |
| Intermountain Health - Intermountain Health West End Clinic /ID# 278470 | Billings, Montana, United States | Recruiting |
| Md Anderson Cancer Center At Cooper /ID# 278390 | Camden, New Jersey, United States | Recruiting |
| SUNY Upstate Medical University - Syracuse /ID# 277245 | Syracuse, New York, United States | Recruiting |
+ 68 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.